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SUMMARY 
 
 Staphylococcus intermedius is the predominant type of coagulase-positive 
staphylococci on normal canine skin (BERG et al., 1984), and is the causative agent of 
pyoderma and otitis externa in dogs (IHRKE et al., 1987). A primary or secondary bacterial 
skin infection determined by bacteria of the Staphylococcus genus is often a component of the 
skin diseases (PELLERIN et al., 1998). The flouoroquinolones have revolutionized treatments 
against bacterial pathogens resistant to traditional antibacterial agents (WALKER, 2000). 
 Enrofloxacin and ciprofloxacin are members of the fluoroquinolones, a class of 
synthetic antibiotics acting on bacterial DNA topoisomerases II and IV and they exhibit high 
bactericidal activity against a broad spectrum of aerobic Gram-negative and Gram-positive 
bacteria and mycoplasmas (HANNAN et al., 1997). 
 In our study we investigated a small collection consisting of 48 S. intermedius strains, 
isolated during a ten-month period and originating from dogs with pyoderma and otitis 
externa and evaluated them against these two fluoroquinolones: enrofloxacin and 
ciprofloxacin. The in vitro antimicrobial susceptibility assay was performed employing the 
disk diffusion method (Kirby-Bauer).  
 The two third generation fluoroquinolones proved to be very active, as the 
susceptibility of S. intermedius strains was 95.83% against enrofloxacin, 93.75% to 
ciprofloxacin, respectively. Only one strain displayed multiple resistances to both tested 
fluoroquinolones. 
 These results are very similar to those obtained by other authors and confirmed the 
excellent activity of fluoroquinolones in treatment of S. intermedius infections.  
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